ClinicalTrials.gg
RecruitingNCT07144800Updated Nov 10, 2026

Family COMIDA (Consumo de Opciones Más Ideales De Alimentos) (Eating More Ideal Food Options)

An interventional study of Parent Weekly Individual Telephone Support and Child Education in Obesity, Child Obesity and Weight Loss, sponsored by Memorial Sloan Kettering Cancer Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-10.

Primary conditionPediatric ObesityRegistry: ObesityReclassifiedWhy we changed it
Registry
Obesity — the first condition term the registry derived for this study.
ClinicalTrials.gg
Pediatric Obesity
Why
  1. The study's listed conditions name Pediatric Obesity, a narrower term within Obesity.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Memorial Sloan Kettering Cancer Center · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 2 months later.
Updated Nov 10, 2026Start date movedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,319
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 558 studies in Pediatric Obesity with a site in United States — 72 open to participants now, 109 under way, 3 of them phase 3. Pediatric Obesity · United States.

Planned enrollment
22nd of 475
1,319 · median 95
Started
2025
with 28 others
No phase
423 of 558
50 open now
Primary completion
2029-07
later than 94 of 108 live
Registered
540th of 558
by date

Among the 558 studies in Pediatric Obesity with a site in United States, this one is the 22nd largest by planned enrollment of the 475 interventional ones that give a count, is one of 29 that started in 2025, is one of 423 with no phase, reaches primary completion later than 94 of the 108 other live ones, and was the 540th registered.

Pediatric Obesity

1,132 studies on the registry are indexed under Pediatric Obesity; 183 are open to participants now.

Browse Pediatric Obesity studies →

Open to participants now

72 of the 558 studies in Pediatric Obesity with a site in United States are open now. Recruiting first, the newest first:

66 more — sign in →

All 72 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 119 Pediatric Obesity studies recruiting now, 16 (13%) set no upper age limit and 101 (85%) stop at 75 or younger; 110 take children under 18; 67 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 558 studies in Pediatric Obesity with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine the most effective family-centered intervention (FCI) for weight loss and obesity prevention in Hispanic families. FCI is a type of program that involves family (such as parents and caregivers) supporting their children to promote healthy habits.

03

Conditions studied

  • Obesity
  • Child Obesity
  • Weight Loss

Browse trials for

Keywords

  • child obesity
  • obesity
  • weight loss
  • Memorial Sloan Kettering Cancer Center
  • 25-003
04

In context

Pediatric Obesity Reclassified

1,132 studies on the registry are indexed under Pediatric Obesity; 183 are open to participants now.

This study's planned enrollment of 1,319 is above the median of 100 across 872 interventional studies indexed under Pediatric Obesity.

Browse Pediatric Obesity studies →

Lead sponsor

Memorial Sloan Kettering Cancer Center is the lead sponsor of 1,964 studies on the registry; 325 are open to participants now.

Of its 135 completed or terminated interventional studies of FDA-regulated products, 71 (53%) have results posted.

Compared within Pediatric Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Obesity. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

The criteria were revised on the registry on Oct 8, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Phase 1

  • Age >= 18 years (per self-report)
  • Self-identifies as Hispanic/Latino (per self-report)
  • Seeking, or has used, services at the VDS or MHU (per self-report)
  • Is the parent or primary caregiver for at least one child aged 8-12 living in their household (per self-report)
  • Screens as obese ( > 30 kg/m2) or overweight (BMI of 25 - 29.9 kg/m2) (per height and weight measurement in person or per self-report)
  • Owns a cell phone capable of receiving text messages (per self-report)
  • Owns an internet connected device (e.g. cell phone, tablet, etc.) capable of conducting videoconference calls (per self-report)
  • Agrees to be audio-recorded (per self-report)

Phase 2 (parent participants)

  • Age >= 18 years (per self-report)
  • Self-identifies as Hispanic/Latino (per self-report)
  • Seeking, or has used, services at the VDS or MHU (per self-report)
  • Is the parent or primary caregiver for at least one child aged 8-12 living in their household (per self-report)
  • Screens as obese (BMI > 30 kg/m2) or overweight (BMI of 25 - 29.9 kg/m2) (per height and weight measurement in person or remotely)
  • Owns a cell phone capable of receiving text messages (per self-report)
  • Owns an internet connected device (e.g. cell phone, tablet, etc.) capable of conducting videoconference calls (per self-report)
  • Agrees to be audio-recorded (per self-report)

Phase 2 (child participants)

  • Age 8-12 years (per parent self-report)
  • Has a parent or primary caregiver who is eligible and participating in Phase 2 (per parent self-report)

Exclusion criteria

Exclusion Criteria:

Phase 1

  • Is pregnant or might be pregnant (per self-report)
  • Presence of a chronic disease such as cancer, kidney disease, liver disease, etc. (individuals with hypertension and diabetes mellitus may still participate) that may affect diet and study participation (per self-report)
  • Has dietary restrictions, i.e. liquid diet, that may affect diet and study participation (per self-report)
  • Has a household member who has already participated or agreed to participate in this study program (per self-report)
  • Prior participation in one of our preliminary studies, e.g., COMIDA, SANOS, Family COMIDA (per self-report) and any related focus groups
  • Works for or with the VDS or MHU (per self-report)
  • Presence of cognitive impairment disorder (i.e., delirium or dementia) sufficient to preclude meaningful and/or data collection (per study team)

Phase 2 (parent participant)

  • Is pregnant or might be pregnant (per self-report)
  • For women, is lactating (per self-report)
  • Presence of a chronic disease such as cancer, kidney disease, liver disease, etc. (individuals with hypertension and diabetes mellitus may still participate) that may affect diet and study participation (per self-report)
  • Has dietary restrictions, i.e., liquid diet, that may affect diet and study participation (per self-report)
  • Has physical activity restrictions, i.e., handicapped or mobility issues, that may affect physical activity participation (increasing step counts; per self-report)
  • Has a household member who has already participated or agreed to participate in this study program (per self-report)
  • Prior participation in one of our preliminary studies, e.g., COMIDA, SANOS, Family COMIDA (per self-report) and any related focus groups
  • Works for or with the VDS or MHU (per self-report)
  • Presence of cognitive impairment disorder (i.e., delirium or dementia) sufficient to preclude meaningful informed consent and/or data collection (per study team)
  • Has been prescribed Ozempic, Wegovy, Mounjaro, Rybelsus, Trulicity (or other GLP 1 receptor agonist), or any other drug to treat obesity (per self-report) or (if previously prescribed) 7 weeks have not passed since the last dose was taken.
  • Has undergone weight loss/bariatric surgery (RYBG, gastric banding, sleeve gastrectomy, balloon, etc.) or is planning to undergo such surgery in the next 12 months (per self-report)

Phase 2 (child participant)

  • Has dietary restrictions, i.e., liquid diet, that may affect diet and study participation (per parent self-report)
  • Has physical activity restrictions, i.e., handicapped or mobility issues, that may affect physical activity participation (per parent self-report)
  • Has an eating disorder (per parent self-report)
  • Is underweight (per parent self-report)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,319 participants (estimated)

Study arms

  • Experimental
    Condition 1: Tele

    Intervention for 6 months more or less

    Behavioral: Parent Weekly Individual Telephone Support

  • Experimental
    Condition 2: Child Education

    Intervention for 6 months

    Behavioral: Child Education

  • Experimental
    Condition 3: Parent Counseling

    Intervention for 6 months

    Behavioral: Parent Initial Counseling

  • Experimental
    Condition 4: Counseling, Child Education, and Tele

    Intervention for 6 months

    Behavioral: Parent Weekly Individual Telephone Support · Behavioral: Child Education · Behavioral: Parent Initial Counseling

  • Experimental
    Condition 5: Group Support

    Intervention for 6 months

    Behavioral: Parent Monthly Group Support

  • Experimental
    Condition 6: Group Support, Child Education, and Tele

    Intervention for 6 months

    Behavioral: Parent Weekly Individual Telephone Support · Behavioral: Child Education · Behavioral: Parent Monthly Group Support

  • Experimental
    Condition 7: Group Support, Parent Counseling, and Tele

    Intervention for 6 months

    Behavioral: Parent Weekly Individual Telephone Support · Behavioral: Parent Initial Counseling · Behavioral: Parent Monthly Group Support

  • Experimental
    Condition 8: Group Support, Parent Counseling, and Child Education

    Intervention for 6 months

    Behavioral: Child Education · Behavioral: Parent Initial Counseling · Behavioral: Parent Monthly Group Support

Interventions

  • BehavioralParent Weekly Individual Telephone Support

    Interventionists will deliver a 20-30 minute session via videoconference (e.g. Zoom) using the Family COMIDA Intervention Manual

    Also known as: Tele

  • BehavioralChild Education

    6 weekly diet/PA education sessions ('Child Education')

  • BehavioralParent Initial Counseling

    Interventionists will deliver a 20-30 minute session via videoconference (e.g. Zoom) using the Family COMIDA Intervention Manual

    Also known as: Parent Counseling

  • BehavioralParent Monthly Group Support

    Parents will be invited to join a Spanish language (English if preferred) weekly group videoconference (can join by phone if preferred).

    Also known as: Group

07

What researchers measure

Primary outcomes

  1. Percentage weight loss from baseline among participants

    To utilize an optimization trial to identify the most effective, mHealth weight loss/obesity prevention FCI for Hispanic families in the U.S. 5% weight loss from baseline among overweight/obese parents (a percentage loss associated with numerous health benefits)

    Time frame: 6 months

08

Study locations

1 of 1 sites recruiting
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities)
    New York, New York 10065, United States
    Recruiting
    • Jennifer Leng, MD, MPH · Contact646-888-8057
09

References and documents

Publications

  • Leng J, Gonzalez-Sarinana LI, Minaya S, Narang B, Gilliland J, Gany F. Finding Balance: Insights from Mexican Heritage Families on Living a Healthy Lifestyle in New York City. J Community Health. 2026 Jul 23. doi: 10.1007/s10900-026-01607-5. Online ahead of print. PubMed 42493744 ↗

Individual participant data

Plan to share: Yes — Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made following one year after publication and for up to 36 months later. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

10

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Jul 2029, 47 months after the start.

Of 542 non-industry interventional studies with no phase under Pediatric Obesity, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 45. This study's planned 47 months is above that.

Counting every sponsor, half of 544 studies reached it within 25 months; a quarter within 11 and three quarters within 45.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Jul 2030 → Jul 2029 and completion Jul 2031 → Jul 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2025
First posted
Aug 28, 2025
StartActual
Aug 26, 2025
Primary completionEst.
Jul 31, 2029was Jul 2030
CompletionEst.
Jul 31, 2029was Jul 2031
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Aug 22, 2025→Aug 26, 2025
Nov 10, 2026
Primary completion
Jul 31, 2030→Jul 31, 2029
Nov 10, 2026
Study completion
Jul 31, 2031→Jul 31, 2029
Nov 10, 2026
Eligibility
2 exclusion criteria added
What changed in the criteria
Exclusion criteria
  • AddedHas been prescribed Ozempic, Wegovy, Mounjaro, Rybelsus, Trulicity (or other GLP 1 receptor agonist), or any other drug to treat obesity (per self-report) or (if previously prescribed) 7 weeks have not passed since the last dose was taken.
  • AddedHas undergone weight loss/bariatric surgery (RYBG, gastric banding, sleeve gastrectomy, balloon, etc.) or is planning to undergo such surgery in the next 12 months (per self-report)
Oct 8, 2026
Show all 2 updates
  1. Nov 10, 2026
    Start date Aug 22, 2025→Aug 26, 2025
    Primary completion Jul 31, 2030→Jul 31, 2029
    Study completion Jul 31, 2031→Jul 31, 2029
    + 1 other change: verification date
  2. Oct 8, 2026
    Eligibility 2 exclusion criteria added
    What changed in the criteria
    Exclusion criteria
    • AddedHas been prescribed Ozempic, Wegovy, Mounjaro, Rybelsus, Trulicity (or other GLP 1 receptor agonist), or any other drug to treat obesity (per self-report) or (if previously prescribed) 7 weeks have not passed since the last dose was taken.
    • AddedHas undergone weight loss/bariatric surgery (RYBG, gastric banding, sleeve gastrectomy, balloon, etc.) or is planning to undergo such surgery in the next 12 months (per self-report)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07144800
Responsible party
Sponsor
First posted
Aug 28, 2025
Start date
Aug 26, 2025
Primary completion
Jul 31, 2029 (estimated)
Completion
Jul 31, 2029 (estimated)
Last update
Nov 10, 2026

Study contacts

Jennifer Leng, MD, MPH
Contact
lengj@mskcc.org
646-888-8057
Francesca Gany, MD, MS
Contact
ganyf@mskcc.org
646-888-8054
Jennifer Leng, MD, MPH
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion